REGN

Regeneron Pharmaceuticals
D

REGN

690.68
USD
3.36
(0.49%)
مفتوح الان
حجم التداول
3,453
الربح لكل سهم
44
العائد الربحي
-
P/E
17
حجم السوق
76,028,170,918
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -2.480
    (-1.44%)
    169.510 USD
    AMGN
    AMGN
    -1.29
    (-0.47%)
    273.23 USD
    BMY
    BMY
    -0.430
    (-0.75%)
    56.620 USD
    GILD
    GILD
    -0.880
    (-0.95%)
    92.070 USD
    JNJ
    JNJ
    -4.765
    (-3.22%)
    143.070 USD
    LLY
    LLY
    10.37
    (1.40%)
    755.39 USD
    MRNA
    MRNA
    3.230
    (9.00%)
    39.120 USD
    NVS
    NVS
    -0.800
    (-0.80%)
    98.850 USD
    PFE
    PFE
    -0.276
    (-1.04%)
    26.330 USD
    المزيد
الأخبار
المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).